(S)-(-)-PERILLYL ALCOHOL
Residual, Progressive or Recurrent Grade II or III Meningioma
Neonc Technologies, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Residual, Progressive or Recurrent Grade II or III Meningioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Essen Biotech | Phase 2 | B |
Fludarabine Essen Biotech | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Anti-Ny Eso-1 Mtcr Pbl National Cancer Institute (NCI) | Phase 2 | B |
Rvp-001 Reveal Pharmaceuticals Inc. | Phase 2 | B |
View all 19 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →